MCID: OPN001
MIFTS: 50

Open-Angle Glaucoma

Categories: Eye diseases, Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Open-Angle Glaucoma

MalaCards integrated aliases for Open-Angle Glaucoma:

Name: Open-Angle Glaucoma 12 15 17
Glaucoma, Open-Angle 44 72
Open Angle Glaucoma 12
Pigmentary Glaucoma 12
Wide-Angle Glaucoma 12
Glaucoma Open-Angle 55
Glaucoma Simplex 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1067
MeSH 44 D005902
NCIt 50 C34641
SNOMED-CT 68 46168003 84494001
UMLS 72 C0017612

Summaries for Open-Angle Glaucoma

Disease Ontology : 12 A glaucoma characterized by optic nerve damage resulting in progressive loss of visual field and increased pressure in the eye due to trabecular blockage.

MalaCards based summary : Open-Angle Glaucoma, also known as glaucoma, open-angle, is related to glaucoma 1, open angle, a and early-onset glaucoma. An important gene associated with Open-Angle Glaucoma is MYOC (Myocilin), and among its related pathways/superpathways are Degradation of the extracellular matrix and Elastic fibre formation. The drugs Dorzolamide and Ketorolac have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and retina, and related phenotypes are homeostasis/metabolism and vision/eye

Related Diseases for Open-Angle Glaucoma

Diseases in the Open-Angle Glaucoma family:

Glaucoma 1, Open Angle, a Glaucoma, Primary Open Angle
Glaucoma 1, Open Angle, P Glaucoma 1, Primary Open Angle, C
Glaucoma 1, Open Angle, D Glaucoma 1, Open Angle, F
Glaucoma 1, Open Angle, B Glaucoma 1, Open Angle, J
Glaucoma 1, Open Angle, K Glaucoma 1, Open Angle, I
Glaucoma 1, Open Angle, G Glaucoma 1, Open Angle, M
Glaucoma 1, Open Angle, N Glaucoma 1, Open Angle, H
Glaucoma 1, Open Angle, O

Diseases related to Open-Angle Glaucoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 332)
# Related Disease Score Top Affiliating Genes
1 glaucoma 1, open angle, a 35.0 OPTN MYOC CYP1B1
2 early-onset glaucoma 33.9 MYOC CYP1B1
3 axenfeld-rieger syndrome 33.0 OPTN CYP1B1 ASB10
4 ocular hypertension 32.9 TMCO1 OPTN MYOC
5 exfoliation syndrome 32.7 MMP1 LOXL1 ELN
6 optic nerve disease 32.3 OPTN OPA1 MYOC
7 primary angle-closure glaucoma 32.2 OPTN MYOC CYP1B1
8 glaucoma, primary open angle 32.0 WDR36 TMCO1 TGFB2 SIX6 OPTN MYOC
9 glaucoma, normal tension 32.0 OPTN OPA1 LOXL1
10 juvenile glaucoma 31.9 WDR36 TGFB2 OPTN NTF4 MYOC ELN
11 primary congenital glaucoma 31.6 WDR36 OPTN MYOC LTBP2 CYP1B1
12 chronic closed-angle glaucoma 31.6 TGFB2 OPTN
13 glaucoma-related pigment dispersion syndrome 31.4 LOXL1 CYP1B1
14 glaucoma 3, primary congenital, a 31.4 OPTN MYOC LTBP2 CYP1B1
15 glaucoma 3, primary infantile, b 31.1 LTBP2 CYP1B1
16 megalocornea 30.9 OPTN LTBP2
17 neovascular glaucoma 30.8 TGFB2 OPTN
18 corneal edema 30.7 OPTN MYOC MMP1 LTBP2 CYP1B1
19 iris disease 30.0 OPTN LOXL1 CRYAA
20 residual stage of open angle glaucoma 12.7
21 glaucoma 1, open angle, p 12.5
22 glaucoma 1, open angle, f 12.4
23 intraocular pressure quantitative trait locus 12.4
24 glaucoma 1, open angle, g 12.4
25 glaucoma 1, open angle, o 12.4
26 glaucoma 1, primary open angle, c 12.1
27 yemenite deaf-blind hypopigmentation syndrome 11.2
28 cataract 11.1
29 myopia 11.1
30 refractive error 10.9
31 eye disease 10.8
32 neuropathy 10.7
33 acrofrontofacionasal dysostosis 10.7 OPTN CYP1B1
34 scotoma 10.7
35 uveitis 10.6
36 hypothyroidism 10.6
37 retinal vascular disease 10.6
38 macular degeneration, age-related, 1 10.6
39 senile cataract 10.6
40 hydrophthalmos 10.6 OPTN LTBP2 CYP1B1
41 3-methylglutaconic aciduria, type iii 10.6
42 vascular disease 10.6
43 retinal detachment 10.6
44 axenfeld-rieger syndrome, type 2 10.6 OPTN ASB10
45 nonarteritic anterior ischemic optic neuropathy 10.6
46 helicobacter pylori infection 10.5
47 retinal vein occlusion 10.5
48 macular retinal edema 10.5
49 48,xyyy 10.5
50 alzheimer disease 10.5

Comorbidity relations with Open-Angle Glaucoma via Phenotypic Disease Network (PDN):


Anatomical Narrow Angle Borderline Glaucoma Glaucoma, Primary Open Angle
Hypertension, Essential Ocular Hypotension

Graphical network of the top 20 diseases related to Open-Angle Glaucoma:



Diseases related to Open-Angle Glaucoma

Symptoms & Phenotypes for Open-Angle Glaucoma

MGI Mouse Phenotypes related to Open-Angle Glaucoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.73 CAV2 CYP1B1 LMX1B LOXL1 MMP1 NTF4
2 vision/eye MP:0005391 9.23 CYP1B1 LMX1B LTBP2 MYOC OPA1 OPTC

Drugs & Therapeutics for Open-Angle Glaucoma

Drugs for Open-Angle Glaucoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 239)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dorzolamide Approved Phase 4 120279-96-1 3154 5284549
2
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
3
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
4
Sorbitol Approved Phase 4 50-70-4 5780
5
Apraclonidine Approved Phase 4 66711-21-5 2216
6
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
7
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 444025 9865442
8
Fluorouracil Approved Phase 4 51-21-8 3385
9
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
10
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
11
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
12
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
13
Polymyxin B Approved, Vet_approved Phase 4 1404-26-8
14
Brinzolamide Approved Phase 4 138890-62-7 68844
15
Bevacizumab Approved, Investigational Phase 4 216974-75-3
16
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 4 303-98-0 5281915
17
Maleic acid Experimental, Investigational Phase 4 110-17-8, 110-16-7 444972
18 Ketorolac Tromethamine Phase 4
19 Lubricant Eye Drops Phase 4
20 Anti-Infective Agents, Local Phase 4
21 Benzalkonium Compounds Phase 4
22 Cathartics Phase 4
23 Laxatives Phase 4
24 Dermatologic Agents Phase 4
25 Dextrans Phase 4
26 Plasma Substitutes Phase 4
27 Anticoagulants Phase 4
28 Blood Substitutes Phase 4
29 Anesthetics Phase 4
30 Anti-Allergic Agents Phase 4
31 Immunosuppressive Agents Phase 4
32 Antimetabolites Phase 4
33 Antimetabolites, Antineoplastic Phase 4
34 HIV Protease Inhibitors Phase 4
35
protease inhibitors Phase 4
36 Anti-Infective Agents Phase 4
37 Polymyxins Phase 4
38 BB 1101 Phase 4
39 Micronutrients Phase 4
40 Nutrients Phase 4
41 Trace Elements Phase 4
42 Ubiquinone Phase 4
43 Pharmaceutical Solutions Phase 4
44 Carbonic Anhydrase Inhibitors Phase 4
45 Angiogenesis Inhibitors Phase 4
46 Angiogenesis Modulating Agents Phase 4
47 Mitomycins Phase 4
48 Brimonidine Tartrate, Timolol Maleate Drug Combination Phase 4
49 Alkylating Agents Phase 4
50 Nucleic Acid Synthesis Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 782)
# Name Status NCT ID Phase Drugs
1 A Study of the Glaukos Trabecular Micro-bypass Stent in Open Angle Glaucoma Subjects 1 Stent Versus 2 Stents Unknown status NCT00326079 Phase 4
2 Semi-Automated Patterned Laser Trabeculoplasty Unknown status NCT00804323 Phase 4
3 Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01% and Lumigan® 0.03% Unit Dose, in Patients With Primary Open Angle Glaucoma or Ocular Hypertension, Stabilized by Lumigan® 0.01% With Ocular Surface Intolerance Unknown status NCT02017327 Phase 4 Monoprost;Lumigan 0.01%;Lumigan 0.03% Unit Dose
4 Phase 4 Study to Evaluate Efficacy And Safety of Three Different Preparations of Latanoprost 0,005% Eyedrops in Subjects Affected by Primary Open Angle Glaucoma Unknown status NCT01580254 Phase 4 IOPIZE© Latanoprost eyedrops;GALAXIA© Latanoprost eyedrops;Latanoprost RATIOPHARM© latanoprost eyedrops
5 An 8 Week Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Open Angle Glaucoma Unknown status NCT02792803 Phase 4 Xalatan;Apo-Latanoprost;Co-Latanoprost
6 Randomized Crossover Trial Comparing the Hypotensive Effect of Generic Travoprost With That of the Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Unknown status NCT02796560 Phase 4 Brand name travoprost;Generic travoprost
7 The Impact of Topical Prostaglandin Analogs on the Biomechanical Properties of the Cornea in Patients With Open Angle Glaucoma Unknown status NCT02388360 Phase 4 topical prostaglandin analogs
8 Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients Unknown status NCT02053298 Phase 4 Timolol & Dorzolamide
9 Comparison of Silicone and Porous Plate Ahmed Glaucoma Valves Unknown status NCT01883856 Phase 4
10 A Prospective, Randomized, Controlled Study to Assess Efficacy,Safety, and Tolerability of Selective Laser Trabeculoplasty vs. Pattern Laser Trabeculoplasty in Patients With Open-angle Glaucoma Unknown status NCT02231515 Phase 4
11 A Randomised Controlled Trial to Compare the Clinical Effectiveness of Selective Laser Trabeculoplasty (SLT) Versus Topical Therapy in the Treatment of Pseudoexfoliative Glaucoma Unknown status NCT01704989 Phase 4 Prostagladin
12 A Pilot Study on the Effects of Cosopt on IOP Lowering and Ocular Diastolic Perfusion Pressure in Patients Not Controlled With Xalatan Monotherapy Unknown status NCT00796198 Phase 4 Xalatan+Cosopt;Xalatan
13 New Horizons in the Treatment of Vitreous Floaters: Efficacy and Safety of Vitreolysis With the Ultra Q Reflex YAG Laser (Ellex) Unknown status NCT02812004 Phase 4
14 A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With Two Trabecular Micro-bypass Stents Completed NCT01252888 Phase 4
15 A Study of the Glaukos Trabecular Micro-Bypass Stent in Refractory Open Angle Glaucoma Subjects. Completed NCT00326040 Phase 4
16 A Study of the Glaukos Trabecular Micro-Bypass Stent in Combination With Cataract Surgery in Open Angle Glaucoma Subjects. Completed NCT00326014 Phase 4
17 Latanoprost Versus Fotil Completed NCT00304785 Phase 4 latanoprost 0.005%;Fotil;placebo
18 A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension Completed NCT02003534 Phase 4 0.15% Brimonidine Tartrate
19 A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension Completed NCT02020512 Phase 4 0.03% Bimatoprost
20 A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) Completed NCT01594970 Phase 4 Bimatoprost 0.01%
21 A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension Completed NCT02061683 Phase 4 Bimatoprost 0.03%
22 A Prospective Evaluation of Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Treated With Two Trabecular Micro-bypass Stents Completed NCT01252862 Phase 4
23 DuoTrav® Eye Drops As Replacement Therapy Program Completed NCT00828906 Phase 4 DuoTrav
24 Lumigan Versus Cosopt Completed NCT00273455 Phase 4 bimatoprost 0.03%;dorzolamide 2%/timolol maleate 0.5% fixed combination;placebo
25 Multi-Center Study Comparing Efficacy and Tolerability of TRAVATAN® BAK-free (0.004% Travoprost) in Patients Previously on Latanoprost Ophthalmic Solution 0.005% Monotherapy Completed NCT01510145 Phase 4 Travoprost 0.004% BAK-free
26 Open Multicenter Study on the Efficacy of Xalatan at 3 Months as First-Line Therapy in Naive Patients With Ocular Hypertension (OH) or Open Angle Glaucoma (OAG), Based on Initial Intraocular Pressure (IOP): 20 mmHg Less Than or Equal to IOP Less Than 24 mmHg, IOP Greater Than or Equal to 24 mmHg Completed NCT00647101 Phase 4 Latanoprost
27 Evaluation of the Safety of GANFORT® (Bimatoprost 0.03% Plus Timolol 0.5%) Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension Completed NCT02571712 Phase 4 bimatoprost 0.03% plus timolol 0.5%
28 Assessing the Safety and Efficacy of Switching to AZARGA® (Brinzolamide/Timolol Fixed Combination) as Replacement Therapy in Patients With Uncontrolled Intraocular Pressure in Taiwan Completed NCT01484951 Phase 4 Brinzolamide 1% and timolol 0.5% fixed combination eye drops
29 ELAZOP Switching Study in Korea Completed NCT01055366 Phase 4 Elazop (Azarga)
30 Efficacy and Safety of Timolol Maleate 0.5% Compared to Brinzolamide 1% When Added to Travoprost 0.004% in Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00372827 Phase 4 Brinzolamide 1% added to Travoprost 0.004%
31 Patient Satisfaction With Timolol Maleate in Sorbate, Generic Timolol Gel Forming Solution or Timolol Hemihydrate in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00804648 Phase 4 Timolol Maleate in Sorbate;Timolol hemihydrate;Timolol maleate gel forming solution
32 Prospective, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of DuoTrav® in Patients Previously Uncontrolled on a Beta-blocker Completed NCT02003391 Phase 4 Beta-blocker monotherapy;Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution
33 Assessment of Late Day IOP Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®) Completed NCT01464424 Phase 4 Travoprost 0.004% ophthalmic solution;Bimatoprost 0.01% ophthalmic solution
34 Assessing the Efficacy and Tolerability of Changing to DUOTRAV® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination), as Replacement Therapy in Patients Previously on Bimatoprost 0.03%/Timolol 0.5% Therapy (Fixed or Unfixed) Completed NCT01327599 Phase 4 Travoprost 0.004%+Timolol 0.5% ophthalmic solution
35 A Prospective, Unmasked, Randomized Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-Angle Glaucoma Completed NCT00913029 Phase 4 latanoprost/timolol
36 A Prospective, Unmasked Evaluation of the iStent in Patients With Primary Open-Angle Glaucoma Completed NCT00911924 Phase 4
37 A Prospective, Randomized Evaluation of Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent) or Travoprost Ophthalmic Solution 0.004% Completed NCT01443988 Phase 4 Travoprost
38 Examination of Ocular Surface Effects With Administration of TRAVATAN Z® and XALATAN® Completed NCT00798759 Phase 4 Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
39 A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Completed NCT00527592 Phase 4 Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
40 24-hour IOP-lowering Effect of Brimonidine 0.1% Completed NCT00457795 Phase 4 brimonidine 0.1% (Alphagan® P)
41 Cosopt Versus Xalatan Completed NCT00273429 Phase 4 timolol maleate 0.5%;dorzolamide/timolol maleate fixed combination;latanoprost 0.005%;placebo
42 Prospective, Randomized, Single-Center Study to Evaluate 24-hour Intraocular Pressure Control With Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination Therapy Completed NCT01978600 Phase 4 Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension;Timolol Maleate 0.5%
43 Post Market Multicentric Evaluation of the AqueSys XEN Implant in Moderate Primary Open Angle Glaucoma Subjects Completed NCT02006693 Phase 4
44 Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00759239 Phase 4 Travoprost 0.004% / Timolol maleate 0.5%;Travoprost 0.004% / Timolol maleate 0.5%
45 The Efficacy and Safety of Brinzolamide 1%/Timolol 0.5% Fixed Combination Versus Dorzolamide 1%/Timolol 0.5% in Patients With Open-Angle Glaucoma and Ocular Hypertension Completed NCT02325518 Phase 4 Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension;Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution;Subject's habitual PGA monotherapy
46 Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Canada Completed NCT01415401 Phase 4 Brinzolamide 1% / timolol 0.5% maleate fixed combination
47 24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients Completed NCT00330577 Phase 4 timolol maleate 0.5%;latanoprost/timolol fixed combination;placebo (artificial tears)
48 A 12-Week Randomized, Evaluator-Masked, Parallel-Group, Multinational, Multi-Center Study Comparing The Efficacy And Safety Of The Fixed Combination Of Latanoprost And Timolol (Xalacom) With The Fixed Combination Of Dorzolamide And Timolol (Cosopt) In Patients With Open-Angle Glaucoma Or Ocular Hypertension. Completed NCT00140049 Phase 4 Xalacom;Cosopt
49 Patient Preference Comparison of AZARGA Versus COSOPT in Patients With Open-Angle Glaucoma or Ocular Hypertension Completed NCT01340014 Phase 4 Brinzolamide 1.0% + Timolol 0.5% ophthalmic suspension;Dorzolamide 2.0% + Timolol 0.5% ophthalmic solution
50 A Multicenter, Open-Label Study To Evaluate The Tolerability Of Preservative Free Dorzolamide-Timolol Therapy In Patients Untreated With Open-Angle Glaucoma Or Ocular Hypertension And Dry Eye(s) Completed NCT00545064 Phase 4 dorzolamide hydrochloride (+) timolol maleate

Search NIH Clinical Center for Open-Angle Glaucoma

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Acetazolamide
Betaxolol
Betaxolol Hydrochloride
bimatoprost
brimonidine
Brimonidine tartrate
brinzolamide
Carbamoylcholine
Carteolol
Carteolol Hydrochloride
Dipivefrin
Dipivefrin hydrochloride
dorzolamide
Dorzolamide hydrochloride
Echothiophate
Echothiophate Iodide
Epinephrine
Epinephrine
epinephrine bitartrate
epinephrine hydrochloride
epinephryl borate
isopropyl unoprostone
latanoprost
Latanoprost
Levobunolol
Levobunolol
Levobunolol Hydrochloride
Methazolamide
Methazolamide
Metipranolol
Metipranolol
Metipranolol hydrochloride
Phenylephrine
Phenylephrine bitartrate
Phenylephrine Hydrochloride
Phenylephrine Tannate
Pilocarpine
Racepinephrine Hydrochloride
Timolol
Timolol Hemihydrate
Timolol Maleate
travoprost
Unoprostone
UNOPROSTONE

Cochrane evidence based reviews: glaucoma, open-angle

Genetic Tests for Open-Angle Glaucoma

Anatomical Context for Open-Angle Glaucoma

MalaCards organs/tissues related to Open-Angle Glaucoma:

41
Eye, Testes, Retina, Endothelial, Brain, Bone, Cortex

Publications for Open-Angle Glaucoma

Articles related to Open-Angle Glaucoma:

(show top 50) (show all 11179)
# Title Authors PMID Year
1
Mutations of optineurin in amyotrophic lateral sclerosis. 9 38
20428114 2010
2
Little evidence for association of the glaucoma gene MYOC with open-angle glaucoma. 9 38
20447966 2010
3
Adenoviral gene transfer of active human transforming growth factor-{beta}2 elevates intraocular pressure and reduces outflow facility in rodent eyes. 9 38
19959644 2010
4
Major LOXL1 risk allele is reversed in exfoliation glaucoma in a black South African population. 9 38
20431720 2010
5
Functional analysis of CYP1B1 mutations and association of heterozygous hypomorphic alleles with primary open-angle glaucoma. 9 38
19793111 2010
6
New mutation in the MYOC gene and its association with primary open-angle glaucoma in a Chinese family. 9 38
19688280 2010
7
Mutation spectrum of the CYP1B1 gene for congenital glaucoma in the Japanese population. 9 38
20151268 2010
8
Myocilin in the trabecular meshwork of eyes with primary open-angle glaucoma. 9 38
19662433 2009
9
A novel optineurin genetic mutation associated with open-angle glaucoma in a Chinese family. 9 38
19710941 2009
10
Correction of the disease phenotype of myocilin-causing glaucoma by a natural osmolyte. 9 38
19234343 2009
11
Genetic risk for primary open-angle glaucoma determined by LMX1B haplotypes. 9 38
18952915 2009
12
Glaucoma-associated myocilin: a better understanding but much more to learn. 9 38
18804106 2009
13
Lack of association between optineurin gene variants T34T, E50K, M98K, 691_692insAG and R545Q and primary open angle glaucoma in Brazilian patients. 9 38
19172505 2009
14
Different WDR36 mutation pattern in Chinese patients with primary open-angle glaucoma. 9 38
19347049 2009
15
Multiple gene polymorphisms analysis revealed a different profile of genetic polymorphisms of primary open-angle glaucoma in northern Chinese. 9 38
19145250 2009
16
Optineurin and its mutants: molecules associated with some forms of glaucoma. 9 38
19672125 2009
17
[Matrix metalloproteinases (MMPs): modern molecular markers of open-angle glaucoma diagnosis and therapy]. 9 38
19002081 2008
18
Two novel myocilin mutations in a Chinese family with primary open-angle glaucoma. 9 38
18776955 2008
19
Elevated amounts of myocilin in the aqueous humor of transgenic mice cause significant changes in ocular gene expression. 9 38
18602390 2008
20
Lack of association between LOXL1 variants and primary open-angle glaucoma in three different populations. 9 38
18421074 2008
21
Lysyl oxidase-like 1 gene polymorphisms in Japanese patients with primary open angle glaucoma and exfoliation syndrome. 9 38
18636115 2008
22
Seed-based systematic discovery of specific transcription factor target genes. 9 38
18485006 2008
23
Leu432Val polymorphism in CYP1B1 as a susceptible factor towards predisposition to primary open-angle glaucoma. 9 38
18483560 2008
24
Gene expression profiles of human trabecular meshwork cells induced by triamcinolone and dexamethasone. 9 38
18436822 2008
25
Transgenic mice expressing the Tyr437His mutant of human myocilin protein develop glaucoma. 9 38
18436825 2008
26
Presence of myocilin sequence variants in Japanese patients with open-angle glaucoma. 9 38
18334962 2008
27
Glutathione S-transferase M1 and T1 polymorphisms in Arab glaucoma patients. 9 38
18334963 2008
28
Absence of optineurin (OPTN) gene mutations in Taiwanese patients with juvenile-onset open-angle glaucoma. 9 38
18385781 2008
29
Myocilin allele-specific glaucoma phenotype database. 9 38
17966125 2008
30
Optineurin coding variants in Ghanaian patients with primary open-angle glaucoma. 9 38
19096531 2008
31
Evaluation of LOXL1 polymorphisms in primary open-angle glaucoma in southern and northern Chinese. 9 38
19098994 2008
32
LOXL1 variants in elderly Japanese patients with exfoliation syndrome/glaucoma, primary open-angle glaucoma, normal tension glaucoma, and cataract. 9 38
18958304 2008
33
Clinical and genetic characteristics of primary juvenile-onset open-angle glaucoma (JOAG). 9 38
18214788 2008
34
Effects of timolol on MYOC, OPTN, and WDR36 RNA levels. 9 38
18195223 2008
35
What increases outflow resistance in primary open-angle glaucoma? 9 38
17998032 2007
36
Suppression of keratoepithelin and myocilin by small interfering RNAs (siRNA) in vitro. 9 38
18079684 2007
37
Association between primary open-angle glaucoma and WDR36 DNA sequence variants in Japanese. 9 38
17960130 2007
38
MYOC gene mutations in Spanish patients with autosomal dominant primary open-angle glaucoma: a founder effect in southeast Spain. 9 38
17893668 2007
39
Identification of mutations in the myocilin (MYOC) gene in Taiwanese patients with juvenile-onset open-angle glaucoma. 9 38
17893664 2007
40
Population differences in elastin maturation in optic nerve head tissue and astrocytes. 9 38
17591890 2007
41
Myocilin variants in Indian patients with open-angle glaucoma. 9 38
17562996 2007
42
Role of MYOC and OPTN sequence variations in Spanish patients with primary open-angle glaucoma. 9 38
17615537 2007
43
[Investigation on the mutation of MYOC gene in two family pedigrees with primary open-angle glaucoma in Shanxi]. 9 38
17867509 2007
44
Role of CYP1B1, MYOC, OPTN, and OPTC genes in adult-onset primary open-angle glaucoma: predominance of CYP1B1 mutations in Indian patients. 9 38
17563717 2007
45
Evaluation of the OPTC gene in primary open angle glaucoma: functional significance of a silent change. 9 38
17359525 2007
46
Bone morphogenetic protein-7 is an antagonist of transforming growth factor-beta2 in human trabecular meshwork cells. 9 38
17251470 2007
47
The OPA1 gene polymorphism is associated with normal tension and high tension glaucoma. 9 38
17188046 2007
48
Aggregated myocilin induces russell bodies and causes apoptosis: implications for the pathogenesis of myocilin-caused primary open-angle glaucoma. 9 38
17200186 2007
49
Suppression of keratoepithelin and myocilin by small interfering RNA (an American Ophthalmological Society thesis). 9 38
18427622 2007
50
SNPs and interaction analyses of noelin 2, myocilin, and optineurin genes in Japanese patients with open-angle glaucoma. 9 38
17122126 2006

Variations for Open-Angle Glaucoma

Expression for Open-Angle Glaucoma

Search GEO for disease gene expression data for Open-Angle Glaucoma.

Pathways for Open-Angle Glaucoma

Pathways related to Open-Angle Glaucoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.09 TGFB2 OPTC MMP1 LTBP2 LOXL1 ELN
2
Show member pathways
10.79 TGFB2 LTBP2 LOXL1 ELN

GO Terms for Open-Angle Glaucoma

Cellular components related to Open-Angle Glaucoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 collagen-containing extracellular matrix GO:0062023 9.26 TGFB2 LTBP2 LOXL1 ELN
2 extracellular matrix GO:0031012 9.02 OPTC MMP1 LTBP2 LOXL1 ELN

Biological processes related to Open-Angle Glaucoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 visual perception GO:0007601 9.02 WDR36 SIX6 OPA1 CYP1B1 CRYAA
2 positive regulation of xenophagy GO:1904417 8.96 TBK1 OPTN

Molecular functions related to Open-Angle Glaucoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix structural constituent GO:0005201 8.8 OPTC LTBP2 ELN

Sources for Open-Angle Glaucoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....